Non-small cell lung cancer (NSCLC) can no longer be considered a homogeneous disease. Histologic and molecular features of NSCLC predict response to targeted agents, as well as certain chemotherapies; therefore, therapy must be individualized according to these criteria to maximize patient outcomes. Gender should also play a role in the individualization of care, as lung cancer biology, natural history, and treatment outcomes vary between men and women. The rapid evolution of the treatment paradigm for NSCLC has generated practice gaps among clinicians surrounding the current best practices that can improve outcomes for NSCLC patients.
Joan H. Schiller, MD
Chief, Division of Hematology and Oncology
Deputy Director of Simmons Comprehensive Cancer Center
Andrea L. Simmons Distinguished Chair in Cancer Research
University of Texas Southwestern Medical Center
Joan H. Schiller, MD is widely published and internationally recognized for her work in lung cancer clinical research. She is the Deputy Director of Simmons Comprehensive Cancer Center, holds the Andrea L. Simmons Distinguished Chair in Cancer Research, and is Division Director of Hematology/Oncology at the University of Texas-Southwestern Medical Center in Dallas, which ranks among the top academic medical centers in the world. Dr. Schiller also is chairperson of the Thoracic Oncology Committee of the Eastern Cooperative Oncology Group, an editor for the Journal of Clinical Oncology, and the principal investigator on many national clinical trials for lung cancer.
Prior to accepting her position in Dallas, for 22 years she was at the University of Wisconsin in Madison where she served as head of the University of Wisconsin Lung Cancer Disease Oriented Working Group, actively treated patients with lung cancer as head of the University of Wisconsin’s Combined Modality Lung Cancer Clinic, and was the principal investigator on many University of Wisconsin clinical trials for lung cancer.
Dr. Schiller graduated from the University of Illinois Medical School and completed her internship and residency in internal medicine at Northwestern Memorial Hospital in Chicago. She then completed a clinical fellowship in the Department of Human Oncology at the University of Wisconsin Comprehensive Cancer Center, where she became the Melanie Heald Professor in the Department of Medicine, Section of Medical Oncology, and subsequently served as head of the Lung Cancer Program at the University of Wisconsin Comprehensive Cancer Center.
Dr. Schiller has served on a variety of American Society of Clinical Oncology (ASCO) committees, including ASCO’s Program Committee, and Chair of ASCO’s Bylaws Committee. She has served on the International Scientific Committee for the 10th and 11th World Conferences on Lung Cancer, and is a board member for the International Association for the Study of Lung Cancer.
Dr. Schiller’s research has generated more than 200 publications that she has authored or co-authored, including articles, abstracts, book chapters, books, reviews, and invited manuscripts.
In 2001, Dr. Schiller formed the National Lung Cancer Partnership with colleagues throughout the nation, and is actively involved in all facets of the organization.
Edward Garon, MD
Physician, Department of Medicine, Hematology/Oncology
Associate Director, JCCC Signal Transduction and Therapeutics Program Area
UCLA Santa Monica Hematology Oncology
Santa Monica, CA
Edward Garon, MD is the Director of the Medical Oncology Program in Thoracic Malignancies at the David Geffen School of Medicine at UCLA. He conducts laboratory-based lung cancer research, as well as clinical research. He has a particular interest in the role of the estrogen receptor pathway in non-small cell lung cancer (NSCLC), and has received federal funding to assess that question. In addition to other clinical trials, Dr. Garon is the national principal investigator of an ongoing clinical trial assessing erlotinib with or without fulvestrant in patients with previously treated, advanced NSCLC.
Heather Wakelee, MD
Department of Medicine, Division of Oncology
Stanford Clinical Cancer Center
Palo Alto, CA
Heather Wakelee, MD is an Assistant Professor of Medicine at Stanford University in the Division of Oncology where she leads the lung cancer medical oncology research program and has authored or co-authored more than 50 medical articles on lung cancer and related topics. She attended Princeton University as an undergraduate with a major in molecular biology and then went to medical school at Johns Hopkins University.
She returned to her native California for an internal medicine residency and fellowship training in medical oncology at Stanford University. Dr. Wakelee’s focus is in clinical research in lung cancer patients. She is the principal investigator of the ongoing international lung cancer intergroup trial E1505 that is investigating the potential role of bevacizumab in addition to adjuvant chemotherapy for resected early stage non-small cell lung cancer (NSCLC). She has a strong interest in the use of adjuvant therapy in lung cancer and frequently lectures on the topic.
Dr. Wakelee has led several investigator-initiated protocols looking at other uses of bevacizumab in NSCLC, as well as playing a central role in clinical trials with many other anti-angiogenic agents. Other pathways of interest include EGFR targeted drugs, especially agents designed to overcome resistance. As part of the developmental therapeutics group at Stanford, Dr. Wakelee is involved in phase I trials of many other exciting novel compounds, with an eye towards further development in lung cancer. She has also worked extensively in sex differences in lung cancer with publications looking at hormone therapy and lung cancer in the Women’s Health Initiative and analyses with the Eastern Cooperative Oncology Group.
This program is intended for medical oncologists, radiation oncologists, surgical oncologists, thoracic surgeons, pulmonologists, NPs, PAs, nurses, fellows and other healthcare professionals who are involved in the care of patients with NSCLC.
This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Discuss the impact of gender on epidemiology of NSCLC
- Discuss the impact of gender on treatment outcomes in NSCLC
- Adequately assess molecular biomarkers and histology reports in order to individualize therapies
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Penn State College of Medicine and Rockpointe. Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 credit(s)™. Physicians should only claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, the post-test, or evaluation, please call Penn State Continuing Education at: 717-531-6483; or e-mail: ContinuingEd@hmc.psu.edu. Please reference activity code G5003-12-T.
Penn State College of Medicine is committed to offering CME/CE programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that our programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty and course directors have disclosed all relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Penn State also requires that faculty disclose any discussion of off-label or investigational uses included in their presentations. Disclosure of a relationship is not intended to suggest or condone bias in a presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute an opinion or endorsement or promotion by Penn State College of Medicine. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Joan H. Schiller, MD: Consultant/Advisor: Aggenix (serves on DSMC), AVEO, Amgen, Bayer, Biodesix, Bristol-Myers Squibb, Daiichi-Sankyo, Lilly, Merck, Oncothyreon, Onyx, Syndax, Telik, Genentech, Novartis, Pfizer (serves on DSMC), Synta, Geron, Celgene, ArQuile, Merrimak; Research Grant: Genentech, Novartis, Pfizer (serves on DSMC), Synta, Geron, Celgene, ArQuile, Merrimak
Edward Garon, MD: Consultant/Advisor: Boehringer-Ingelheim; Research Grant: Pfizer, Eli Lilly, Novartis, Genentech, AstraZeneca, GlaxoSmithKline
Heather Wakelee, MD: Clinical Trial: Genentech, Exelixis, Regeneron, AstraZeneca, Pfizer, Lilly, Bayer, Novartis
Planner and Manager Disclosures
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests: Rockpointe Corporation and Penn State College of Medicine staff involved with this activity have nothing to disclose.
Academic Reviewer for Penn State College of Medicine Chandra P. Belani, MD: Consultant/Advisor: Eli Lilly, Genentech
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.
Instructions for Participants and Obtaining CME Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive and print their certificates, participants must demonstrate mastery of the presented material via the post-test.
Jointly Sponsored By
|This activity is jointly sponsored by
Supported by an independent educational grant from Genentech BioOncology & Lilly USA, LLC.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.